Oric Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

ORIC$8.82+3.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	September 30, 2025	December 31, 2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$49,668	$59,406
Short-term investments	237,472	196,554
Prepaid expenses and other current assets	8,454	6,290
Total current assets	295,594	262,250
Long-term investments	125,908	—
Property and equipment, net	2,559	2,924
Other assets	7,131	8,968
Total assets	$431,192	$274,142
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,900	$1,548
Accrued liabilities	17,279	23,298
Total current liabilities	20,179	24,846
Other long-term liabilities	4,094	6,174
Total liabilities	24,273	31,020
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 97,278,032 and 71,021,855 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	11	7
Additional paid-in capital	1,068,030	805,510
Accumulated deficit	(661,737)	(562,774)
Accumulated other comprehensive income	615	379
Total stockholders' equity	406,919	243,122
Total liabilities and stockholders' equity	$431,192	$274,142

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.